Get the Stockscreener App
115.77
0.16%
-0.19
After Hours:
115.77
Novartis Ag Adr stock is traded at $115.77, with a volume of 2.47M.
It is down -0.16% in the last 24 hours and up +3.11% over the past month.
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
See More
Previous Close:
$115.96
Open:
$116.74
24h Volume:
2.47M
Relative Volume:
1.20
Market Cap:
$234.21B
Revenue:
$53.22B
Net Income/Loss:
$12.86B
P/E Ratio:
18.12
EPS:
6.39
Net Cash Flow:
$14.85B
1W Performance:
-3.08%
1M Performance:
+3.11%
6M Performance:
+19.22%
1Y Performance:
+9.49%
1-Day Range:
$115.43
$116.74
1-Week Range:
$115.43
$119.53
52-Week Range:
$96.06
$120.92
Novartis Ag Adr Stock (NVS) Company Profile
Name
Novartis Ag Adr
Sector
Industry
Phone
-
Address
-
Compare NVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVS
Novartis Ag Adr
|
115.77 | 234.21B | 53.22B | 12.86B | 14.85B | 6.39 |
|
LLY
Lilly Eli Co
|
762.73 | 724.64B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
149.79 | 376.43B | 89.33B | 21.81B | 18.57B | 8.99 |
|
NVO
Novo Nordisk Adr
|
73.77 | 352.49B | 43.59B | 15.04B | 10.74B | 3.3766 |
|
ABBV
Abbvie Inc
|
185.30 | 334.73B | 57.37B | 4.20B | 15.39B | 2.35 |
Novartis Ag Adr Stock (NVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-13-25 | Downgrade | UBS | Buy → Neutral |
| Feb-12-25 | Initiated | Morgan Stanley | Underweight |
| Feb-04-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Dec-04-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Sep-11-24 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-05-24 | Downgrade | Goldman | Buy → Neutral |
| Sep-03-24 | Downgrade | Jefferies | Buy → Hold |
| Jul-19-24 | Downgrade | Deutsche Bank | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Feb-23-24 | Initiated | BMO Capital Markets | Market Perform |
| Jan-23-24 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-16-24 | Resumed | UBS | Buy |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-25-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-26-23 | Upgrade | Deutsche Bank | Hold → Buy |
| Mar-27-23 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-26-23 | Downgrade | Citigroup | Buy → Neutral |
| Dec-05-22 | Upgrade | Stifel | Hold → Buy |
| Sep-15-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| May-09-22 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-10-22 | Resumed | Citigroup | Buy |
| Dec-14-21 | Downgrade | Redburn | Buy → Neutral |
| Dec-06-21 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Dec-03-21 | Downgrade | Bryan Garnier | Buy → Neutral |
| Sep-20-21 | Downgrade | Deutsche Bank | Hold → Sell |
| Mar-22-21 | Initiated | Bernstein | Mkt Perform |
| Mar-10-21 | Downgrade | Argus | Buy → Hold |
| Feb-01-21 | Downgrade | Cowen | Outperform → Market Perform |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Sep-10-20 | Upgrade | UBS | Neutral → Buy |
| Sep-01-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-15-20 | Upgrade | Citigroup | Neutral → Buy |
| Mar-10-20 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-25-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-25-19 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-10-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-02-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-11-18 | Resumed | Jefferies | Buy |
| Oct-09-18 | Initiated | Guggenheim | Neutral |
| Sep-10-18 | Upgrade | BofA/Merrill | Underperform → Buy |
| May-29-18 | Downgrade | HSBC Securities | Buy → Hold |
| May-25-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jan-25-18 | Reiterated | Leerink Partners | Outperform |
| Dec-06-17 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jul-26-17 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jul-05-17 | Downgrade | Credit Suisse | Neutral → Underperform |
| Mar-09-17 | Initiated | Liberum | Buy |
View All
Novartis Ag Adr Stock (NVS) Latest News
Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study - GlobeNewswire Inc.
The Novartis Oncology Young Canadian Investigator Awards (NOYCIA) returns for its 22nd year at ASCO 2025 - Barchart.com
Penicillin Market Research Report 2025 - GlobeNewswire Inc.
Why Value Investing Has Worked Better Outside the US - Morningstar
Regeneron Initial Data On Multiple Myeloma Drug Encouraging - Barchart.com
Bybit Gold & FX now supports stock trading: Explore new markets! - Bybit Announcement
GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug - Yahoo Finance
Novartis Canada extends Health Equity Initiative effort, fueling innovation and impact for second year - Barchart.com
NVS’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
Novartis Earnings: Strong First-Quarter Supports Increased Full-Year Guidance - Morningstar
Novartis ADR earnings beat by $0.20, revenue topped estimates - Investing.com
Novartis Holds a Strong Branded Drug Portfolio Supporting Steady Long-Term Growth - Morningstar
Novartis Beats On Q1 Earnings And Sales, Raises Guidance, Stock Up - Barchart.com
Roche to invest US$50-billion in U.S. to avoid Trump tariffs, create 12,000 jobs - The Globe and Mail
Novartis to Report Q1 Earnings: Will Key Drugs Maintain Momentum? - Yahoo Finance
Swiss pharmaceutical giant announces plans for $1.1B campus in San Diego - fox5sandiego.com
Stocks to Watch Friday: JPMorgan, Wells Fargo, BlackRock, Newmont - WSJ
Pharma Stock Roundup: EU Nod To Expanded Use Of ABBV, AZN Drugs & More - Barchart.com
Pharma Stock Roundup: FDA Nod To SNY, AZN & NVS, JNJ Talc Suits Failure - Barchart.com
FDA Grants Accelerated Approval To NVS Kidney Disease Drug - Barchart.com
Quantum Corp’s Banking’s 100-Day Moving Average at 21.57: Will the Stock Break Through? - investchronicle.com
No room on the ARK? - Morningstar
5 Large Drug Stocks To Watch As Industry Recovers - Barchart
FDA Approves Novartis Drug For Rare Kidney Disease Treatment - Barchart
Novartis scraps use of diverse panels for hires in US - Reuters
Alnylam Rallies 62% In A Year: Can The Stock Maintain This Momentum? - Barchart
Bioengineered Protein Drugs Market Size to Cross USD 672.7 Billion by 2034, Growing at a CAGR of 6.2% - GlobeNewswire Inc.
Novartis becomes NFL’s first pharmaceutical partner By Investing.com - Investing.com India
Complement C4 Antibody Market Research 2025: Growing Focus on Precision Medicine and Targeted Therapies, and Increasing Investment in Immunotherapies and Biologic Drugs - GlobeNewswire Inc.
Alberta sets a new standard for advanced prostate cancer treatment with public reimbursement of Pluvicto™ - Barchart
Giovanni Caforio, M.D. - Novartis
Novartis Ag Adr Stock (NVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.29%
0.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):